Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review (Q38181169)

30 August 2017

title

Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review (English)

1 reference

30 August 2017

1 reference

1 reference

Terence T Sio

1

1 reference

30 August 2017

Jocelyn Ko

2

1 reference

30 August 2017

Vinay K Gudena

3

1 reference

30 August 2017

Nitin Verma

4

1 reference

30 August 2017

Uzair B Chaudhary

5

1 reference

30 August 2017

publication date

23 January 2014

1 reference

International Journal of Urology

30 August 2017

published in

1 reference

30 August 2017

volume

21

1 reference

30 August 2017

issue

7

1 reference

30 August 2017

page(s)

630-637

1 reference

30 August 2017

cites work

Cancer statistics, 2012

1 reference

Metastatic bladder cancer: advances in treatment

21 January 2018

1 reference

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder

21 January 2018

1 reference

Combination Chemotherapy with cis-Diamminedichloroplatinum (II) and Bleomycin in Tumors of the Head and Neck

21 January 2018

1 reference

Systemic chemotherapy in inoperable or metastatic bladder cancer

21 January 2018

1 reference

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment

21 January 2018

1 reference

Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

21 January 2018

1 reference

A nonplatinum combination in metastatic transitional cell carcinoma

21 January 2018

1 reference

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study

21 January 2018

1 reference

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma

21 January 2018

1 reference

Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens

21 January 2018

1 reference

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

21 January 2018

1 reference

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

21 January 2018

1 reference

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

21 January 2018

1 reference

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer

21 January 2018

1 reference

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IJU.12407

1 reference

30 August 2017

1 reference